MARKET

BLPH

BLPH

Bellerophon Therapeutics Inc
NASDAQ
1.090
+0.060
+5.83%
After Hours: 1.050 -0.04 -3.67% 17:38 09/30 EDT
OPEN
0.9801
PREV CLOSE
1.030
HIGH
1.100
LOW
0.9800
VOLUME
13.41K
TURNOVER
0
52 WEEK HIGH
4.490
52 WEEK LOW
0.6700
MARKET CAP
10.40M
P/E (TTM)
-0.5567
1D
5D
1M
3M
1Y
5Y
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers
Benzinga · 4d ago
Nasdaq Turns Higher; Crude Oil Rises Over 2%
U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday.
Benzinga · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers
Benzinga · 4d ago
US Stocks Turn Lower; Dow Dips 175 Points
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday.
Benzinga · 4d ago
Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 4d ago
Why Are Bellerophon Shares Jumping Today?
Benzinga · 4d ago
Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Bellerophon Therapeutics (NASDAQ:BLPH) on Tuesday ...
Seekingalpha · 4d ago
BRIEF-Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
BRIEF-Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
Reuters · 5d ago
More
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of its clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. It has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.